CN103826641B - 作为蛋白激酶抑制剂的含磷化合物 - Google Patents

作为蛋白激酶抑制剂的含磷化合物 Download PDF

Info

Publication number
CN103826641B
CN103826641B CN201280008209.1A CN201280008209A CN103826641B CN 103826641 B CN103826641 B CN 103826641B CN 201280008209 A CN201280008209 A CN 201280008209A CN 103826641 B CN103826641 B CN 103826641B
Authority
CN
China
Prior art keywords
alk
substituted
fluoro
unsubstituted
ethyoxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280008209.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103826641A (zh
Inventor
胡百华
何坎
张民生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN103826641A publication Critical patent/CN103826641A/zh
Application granted granted Critical
Publication of CN103826641B publication Critical patent/CN103826641B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280008209.1A 2011-02-24 2012-02-22 作为蛋白激酶抑制剂的含磷化合物 Active CN103826641B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446321P 2011-02-24 2011-02-24
US61/446,321 2011-02-24
PCT/US2012/026083 WO2012116050A2 (en) 2011-02-24 2012-02-22 Phosphorus containing compounds as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CN103826641A CN103826641A (zh) 2014-05-28
CN103826641B true CN103826641B (zh) 2018-09-07

Family

ID=46719414

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280008209.1A Active CN103826641B (zh) 2011-02-24 2012-02-22 作为蛋白激酶抑制剂的含磷化合物

Country Status (11)

Country Link
US (1) US8951993B2 (ru)
EP (1) EP2678021A4 (ru)
JP (1) JP5965923B2 (ru)
KR (1) KR20140023886A (ru)
CN (1) CN103826641B (ru)
BR (1) BR112013020975A2 (ru)
CA (1) CA2826892A1 (ru)
MX (1) MX2013009551A (ru)
RU (1) RU2598849C2 (ru)
WO (1) WO2012116050A2 (ru)
ZA (1) ZA201306025B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138751A2 (en) * 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
EP2758387A4 (en) * 2011-09-21 2015-03-11 Teligene Ltd Pyridine compounds as kinase inhibitors
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
JP6205216B2 (ja) * 2012-09-24 2017-09-27 アークレイ株式会社 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット
RU2671212C2 (ru) * 2013-02-02 2018-10-30 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд Замещенный 2-аминопиридин в качестве ингибитора протеинкиназы
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US9981946B2 (en) 2014-07-31 2018-05-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyridine-substituted 2-aminopyridine protein kinase inhibitors
CN105330697B (zh) * 2014-08-07 2019-05-28 江苏豪森药业集团有限公司 一种抗癌化合物的晶型及其制备方法和用途
CN106661064B (zh) * 2014-08-07 2019-10-15 江苏豪森药业集团有限公司 一种抗癌化合物的新晶型及其制备方法和用途
WO2016019910A1 (zh) * 2014-08-07 2016-02-11 江苏豪森药业股份有限公司 一种抗癌化合物的晶型及其制备方法和用途
CN106957336B (zh) * 2016-01-12 2021-02-12 江苏豪森药业集团有限公司 氟卓替尼的制备方法
CN106496192B (zh) * 2016-08-31 2019-01-01 北京凯悦宁医药科技有限公司 一种克里唑蒂尼或氘代克里唑蒂尼的制备方法
CN106632260B (zh) * 2016-09-29 2019-04-26 上海天慈生物谷生物工程有限公司 一种小分子激酶抑制剂的制备方法
WO2024088398A1 (zh) * 2022-10-27 2024-05-02 勤浩医药（苏州）有限公司 含磷化合物、药物组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319493A1 (en) * 1998-03-18 1999-09-23 Regine Bohacek Heterocyclic signal transduction inhibitors, compositions containing them
CA2343027A1 (en) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
JP4234344B2 (ja) * 1999-12-28 2009-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有複素環化合物
ES2401330T3 (es) * 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas
EP1610793A2 (en) * 2003-03-25 2006-01-04 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
BRPI0514687A (pt) * 2004-08-26 2008-06-17 Pfizer compostos amino heteroarila como inibidores de proteìna tirosina cinase
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
WO2007081630A2 (en) * 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Substituted pyrimidinyl kinase inhibitors
NO2300013T3 (ru) * 2008-05-21 2018-02-03
US8193372B2 (en) * 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors

Also Published As

Publication number Publication date
KR20140023886A (ko) 2014-02-27
EP2678021A4 (en) 2015-07-01
US8951993B2 (en) 2015-02-10
US20120220551A1 (en) 2012-08-30
WO2012116050A2 (en) 2012-08-30
RU2013141274A (ru) 2015-03-27
JP5965923B2 (ja) 2016-08-10
MX2013009551A (es) 2013-09-06
EP2678021A2 (en) 2014-01-01
CN103826641A (zh) 2014-05-28
RU2598849C2 (ru) 2016-09-27
ZA201306025B (en) 2016-02-24
JP2014515006A (ja) 2014-06-26
CA2826892A1 (en) 2012-08-30
WO2012116050A3 (en) 2014-04-17
BR112013020975A2 (pt) 2016-10-11

Similar Documents

Publication Publication Date Title
CN103826641B (zh) 作为蛋白激酶抑制剂的含磷化合物
CN102448955B (zh) 氨基嘧啶抗癌化合物
KR101749192B1 (ko) 트리아진, 피리미딘 및 피리딘 유사체 및 이의 치료제 및 진단 프로브로의 용도
TWI622587B (zh) 二雜芳基化合物及其用途
WO2014183520A1 (zh) 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN104024254A (zh) 作为c-Kit激酶抑制剂的化合物和组合物
CN103153982A (zh) 作为alk抑制剂的4-(1h-吲哚-3-基)-嘧啶
JP2010538094A (ja) チロシンキナーゼ阻害剤としてのピラゾロピリジン類
JP2022532850A (ja) ４ｈ－ピロロ［３，２－ｃ］ピリジン－４－オン化合物
CN109851638B (zh) 取代的二氨基嘧啶化合物
WO2004043936A1 (ja) Ｐｌｋ阻害剤
BR112013008523B1 (pt) Compostos de piridazina carboxamida substituídos e usos dos mesmos para tratar câncer, uma doença de proliferação, uma doença neurológica, uma doença psiquiátrica, obesidade, diabetes ou doença cardiovascular
CN101679418A (zh) 用作蛋白质激酶抑制剂的[2,6]萘啶类化合物
CN113490670B (zh) 含氮多环稠环类化合物,其药物组合物、制备方法和用途
EA005297B1 (ru) ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА И 7-ПИРИДИНИЛ-2,3-ДИГИДРОИМИДАЗО[1,2-a]ПИРИМИДИН-5(1H)ОНА
CN115073469A (zh) 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用
AU2012257345B2 (en) Substituted indole derivatives for the treatment of immunological disorders
JP2022511236A (ja) 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用
AU2012257345A1 (en) Substituted indole derivatives for the treatment of immunological disorders
CN110734426B (zh) 乙酰胆碱酯酶降解化合物及其制备方法和应用
TWI680128B (zh) 二氫吡咯並吡啶衍生物
KR20150092301A (ko) 암, 바이러스성 감염 및 폐질환의 치료를 위한 인돌의 새로운 유도체
CN115028633A (zh) 吡咯并嘧啶类化合物的制备及其应用
TW202146404A (zh) 嘧啶化合物及其醫藥用途
TW201902892A (zh) 化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047

Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd.

Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047

Applicant before: Jiangsu best Pharmaceutical Co.,Ltd.

Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047

Applicant after: Jiangsu best Pharmaceutical Co.,Ltd.

Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047

Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd.

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant